Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H32N2O2S |
| Molecular Weight | 400.577 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CCOC1=CC=C(NC(=S)NC2=CC=C(OCCC(C)C)C=C2)C=C1
InChI
InChIKey=BWBONKHPVHMQHE-UHFFFAOYSA-N
InChI=1S/C23H32N2O2S/c1-17(2)13-15-26-21-9-5-19(6-10-21)24-23(28)25-20-7-11-22(12-8-20)27-16-14-18(3)4/h5-12,17-18H,13-16H2,1-4H3,(H2,24,25,28)
| Molecular Formula | C23H32N2O2S |
| Molecular Weight | 400.577 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Thiocarlide (or tiocarlide or isoxyl) is a drug which was used in the treatment of tuberculosis. In addition was preclinical experiments, which showed, that it purely bacteriostatic against M. leprae. The precise mechanism is still unknown but was shown, that Delta9-desaturase could be a target for it. The more recent experiments have revealed, that Thiocarlide inhibits the dehydration step by the (3R)-hydroxyacyl dehydratases HadAB and HadBC.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P9WNZ3 Gene ID: 888821.0 Gene Symbol: desA3 Target Organism: Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Sources: https://www.ncbi.nlm.nih.gov/pubmed/14559907 |
|||
Target ID: HadAB and/or HadBC Sources: https://www.ncbi.nlm.nih.gov/pubmed/23002234 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/58847 |
Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. | 2012-11-09 |
|
| Isoxyl particles for pulmonary delivery: In vitro cytotoxicity and potency. | 2010-08-30 |
|
| EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. | 2007-03 |
|
| Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis. | 2006-09-15 |
|
| Novel heteroarotinoids as potential antagonists of Mycobacterium bovis BCG. | 2004-02-12 |
|
| The use of microarray analysis to determine the gene expression profiles of Mycobacterium tuberculosis in response to anti-bacterial compounds. | 2004 |
|
| Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. | 2003-12-26 |
|
| Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. | 2000-06-02 |
|
| Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. | 1999-05 |
|
| [Antitubercular agents. 44. N,N-dialkyldithiooxamide]. | 1988-11 |
|
| Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. | 1971-06 |
|
| [Simultaneous determination of double labelled isoxyl (3H and 35S) blood levels in man, by radio- and bio-assays]. | 1968 |
|
| Experimental studies on therapeutic effects of various combinations of antituberculosis drugs. II. Comparison of various regimens in treatment of experimental mouse tuberculosis infected with SM- and INH-resistant Schacht strain. | 1967-07 |
|
| [Bacteriologic blood level examination in mono-medication with pulverized Isoxyl (diisoamyloxythiocarbanilide)]. | 1967 |
|
| Study of the toxicity of isoxyl. Research on the pathological effects of isoxyl in the rat undergoing chronic experimentation. | 1966-07 |
|
| Thiocarlide (4'4-diisoamyloxythiocarbanilide) blood levels in patients suffering from tuberculosis. | 1966-06 |
|
| Absorption and excretion studies with thiocarlide (4'4-diisoamyloxythiocarbanilide) in man. | 1966-06 |
|
| THE EFFECTIVENESS OF A THIOCARBANILIDE (ISOXYL) AS A THERAPEUTIC DRUG IN MOUSE TUBERCULOSIS. | 1963-11 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5963588
3 g in tablet form (6 tablets of 0.5 g) repeated after six hours.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14559907
The specific inhibition of oleic acid synthesis by thiocarlide (ISO) suggested that the drug target is the aerobic desaturation system responsible for the synthesis of oleic acid from stearoyl-CoA in mycobacteria. To test this hypothesis Mycobacterium bovis BCG strain was grown in iron-supplemented medium, sonicated, and centrifuged at low speed, and both the cell wall pellet and the supernatant containing both cytosol and plasma membrane were assayed for Δ9 fatty acid desaturase activity. The assay was performed as originally described by Fulco and Bloch with minor modifications. Consistent with the findings of Fulco and Bloch in the absence of NADPH in the assay mixture, no oleic acid was detected. ISO consistently inhibited the incorporation of radioactivity into the oleic acid, but not into stearic acid, by 7% at 0.1 μg/ml and 61% at a concentration of 1.0 μg of ISO/ml in one typical experiment.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:16:37 GMT 2025
by
admin
on
Wed Apr 02 09:16:37 GMT 2025
|
| Record UNII |
43M23X81Y2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
J04AD02
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
||
|
NCI_THESAURUS |
C280
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
||
|
WHO-VATC |
QJ04AD02
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
43M23X81Y2
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
910-86-1
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
THIOCARLIDE
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
DTXSID70238358
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
m968
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | Merck Index | ||
|
2673
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
CHEMBL214920
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
213-006-5
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
742400
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
3001386
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
C152637
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
DB13608
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
C100189
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
100000077209
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
SUB11078MIG
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY | |||
|
1597
Created by
admin on Wed Apr 02 09:16:37 GMT 2025 , Edited by admin on Wed Apr 02 09:16:37 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |